ecancermedicalscience最新文献

筛选
英文 中文
Prevalence and associated factors of herbal medicine use among breast cancer patients: a cross-sectional study in Morocco. 乳腺癌患者中草药使用的患病率及相关因素:摩洛哥的一项横断面研究
IF 1.2
ecancermedicalscience Pub Date : 2024-10-09 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1786
Anass Baladi, Mohammed El Fadli, Hassan Abdelilah Tafenzi, Kawtar El Bouaouidi, Nada Benhima, Leila Afani, Ismail Essâdi, Rhizlane Belbaraka
{"title":"Prevalence and associated factors of herbal medicine use among breast cancer patients: a cross-sectional study in Morocco.","authors":"Anass Baladi, Mohammed El Fadli, Hassan Abdelilah Tafenzi, Kawtar El Bouaouidi, Nada Benhima, Leila Afani, Ismail Essâdi, Rhizlane Belbaraka","doi":"10.3332/ecancer.2024.1786","DOIUrl":"10.3332/ecancer.2024.1786","url":null,"abstract":"<p><strong>Background: </strong>Despite advances in modern medicine, an increasing number of breast cancer (BC) patients are turning to complementary and alternative medicine, such as phytotherapy. Instead of being prescribed by breast medical oncologists, patients are often seeking out phytotherapy themselves. They typically resort to herbal medicine as an alternative treatment to alleviate symptoms and side effects and enhance their quality of life during cancer treatment. This study, conducted in Morocco, aimed to investigate the prevalence and associated factors of herbal medicine use among BC patients.</p><p><strong>Methods: </strong>A cross-sectional study of 170 patients with BC was carried out from October 2021 to January 2022 at the Mohamed VI University Hospital in Marrakech. Participants were selected using convenience sampling based on specific criteria such as being over 18 years old, having a histological diagnosis of BC, and being in active treatment. Data were collected through a structured questionnaire administered by trained clinicians, and medical records were reviewed for clinical data. Statistical analysis was conducted using Microsoft Forms for data collection and SPSS version 26 for statistical analysis. Descriptive statistics summarised demographic and health-related characteristics. Associations between herbal medicine use and categorical variables were assessed using chi-square and Fisher exact tests. Logistic regression analyses were performed to identify predictors of herbal medicine use, with statistical significance set at <i>p</i> < 0.05.</p><p><strong>Results: </strong>Among the 170 BC patients included in the study, 37% reported using phytotherapeutics. One of the significant findings of this study was that nearly half of the BC patients surveyed believed herbal remedies to be harmless. None of the patients received information about herbal medicine use from their attending physicians. The use of herbal medication was significantly associated with marital status adjusted odds ratio (AOR: NR, <i>p</i> = 0.019), residence (AOR: 2.291, 95% confidence interval (CI): 1.214-4.324, <i>p</i> = 0.019), education levels (AOR: NR, <i>p</i> = 0.04) and receipt of radiotherapy (AOR: 0.128, 95% CI: 0.016-1.007, <i>p</i> = 0.023). Widowed women had a four times higher probability of using medicinal herbs than single or divorced women (AOR: 4.95, 95% CI: 1.16-20.90, <i>p</i> = 0.03). Illiterate women (AOR: 0.18, 95% CI: 0.052-0.65, <i>p</i> = 0.009) or those who attended Koranic school (AOR: 0.04, 95% CI: 0.004-0.47, <i>p</i> = 0.01) were less likely to use herbal medicine. Urban women were about twice as likely to use herbal remedies as women from rural areas (AOR: 2.02, 95% CI: 1.002-4.09, <i>p</i> = 0.049).</p><p><strong>Conclusion: </strong>This study highlights the need for healthcare professionals to be aware of their patients' possible use of herbal medicine, be familiar with commonly used herbal treatments, and take proa","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1786"},"PeriodicalIF":1.2,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nasopharyngeal, tongue and laryngeal cancer in Southern Ethiopia: a seven-year retrospective cross-sectional review. 埃塞俄比亚南部鼻咽癌、舌癌和喉癌:7年回顾性横断面回顾。
IF 1.2
ecancermedicalscience Pub Date : 2024-10-08 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1784
Achamyelesh Gebretsadik, Netsanet Bogale, Dereje Geleta, Nebiyu Melaku, Dubale Dulla
{"title":"Nasopharyngeal, tongue and laryngeal cancer in Southern Ethiopia: a seven-year retrospective cross-sectional review.","authors":"Achamyelesh Gebretsadik, Netsanet Bogale, Dereje Geleta, Nebiyu Melaku, Dubale Dulla","doi":"10.3332/ecancer.2024.1784","DOIUrl":"10.3332/ecancer.2024.1784","url":null,"abstract":"<p><strong>Background: </strong>The burden of cancer is increasing globally and is having a negative impact on people's physical, mental and financial health. On the other hand, developing countries are not progressing to prevent the disease at the same rate as the disease burden increases. The development of strategies for cancer prevention, control and treatment that contribute to the community's improved health requires knowledge of cancer epidemiologic data. There is relatively little epidemiologic evidence of nasopharyngeal, tongue and laryngeal cancer in southern Ethiopia. This study aimed to assess the epidemiological burden of nasopharyngeal, tongue and laryngeal cancer among patients treated at Hawassa University Comprehensive and Specialised Hospital (HUCSH) between 2013 and 2019.</p><p><strong>Methods: </strong>A cross-sectional retrospective review was conducted among 3,002 patients who attended the oncologic care at HUCSH. Data were retrieved between February and May 2020. Data were entered using Epi-data version 3.1 and the data were then exported to IBM SPSS version 22 (IBM Corporation, Armonk, NY, USA) for further processing and analysis. A descriptive analysis was done.</p><p><strong>Result: </strong>A total of 280 (9.3%) new head and neck cancer (HNC) patients were identified over a period of 7 years. Nasopharyngeal cancer accounts for more than one-fourth (26.4%) of all HNCs, followed by tongue 15% and laryngeal 14.6% cancers. Males constituted nearly two-thirds of the cases. The overall caseloads doubled over the retrieved years.</p><p><strong>Conclusion: </strong>According to this study, nasopharyngeal, tongue and laryngeal cancer is a more prominent cause of morbidity. According to place, person and time, the frequency of nasopharyngeal, tongue and laryngeal cancer steadily rose in both sexes and across all age categories. Therefore, immediate intervention is needed nationwide to monitor the disease's explosive growth.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1784"},"PeriodicalIF":1.2,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of bacterial vaginosis, sexually transmitted infections and their association with HPV infections in asymptomatic women attending antenatal care in Ethiopia. 埃塞俄比亚无症状妇女产前检查中细菌性阴道病、性传播感染及其与人乳头瘤病毒感染的关系。
IF 1.2
ecancermedicalscience Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1783
Johanna M A Klein, Isabel Runge, Ann-Katrin Pannen, Tariku Wakuma, Semaw Ferede Abera, Adamu Adissie, Susanne Unverzagt, Markus Schmitt, Tim Waterboer, Daniela Höfler, Christoph Thomssen, Eva Johanna Kantelhardt
{"title":"Prevalence of bacterial vaginosis, sexually transmitted infections and their association with HPV infections in asymptomatic women attending antenatal care in Ethiopia.","authors":"Johanna M A Klein, Isabel Runge, Ann-Katrin Pannen, Tariku Wakuma, Semaw Ferede Abera, Adamu Adissie, Susanne Unverzagt, Markus Schmitt, Tim Waterboer, Daniela Höfler, Christoph Thomssen, Eva Johanna Kantelhardt","doi":"10.3332/ecancer.2024.1783","DOIUrl":"10.3332/ecancer.2024.1783","url":null,"abstract":"<p><p>Sexually transmitted infections (STIs) and human papillomavirus (HPV) infections are common among women of reproductive age and can lead to infertility, adverse pregnancy outcomes, neonatal infections and cervical cancer. In countries with limited medical coverage, untreated infections contribute to high morbidity. This study aimed to expand the current knowledge on the prevalence of bacterial vaginosis (BV) and STIs in pregnant Ethiopian women and assess the association of these conditions with HPV infections. Socio-demographic data and vaginal lavage samples were collected from 779 asymptomatic women aged 18 to 45 years (median age, 25.9 years) attending antenatal care in seven centres across Ethiopia. Multiplex polymerase chain reaction was used to test for BV, <i>Chlamydia trachomatis</i>, <i>Trichomonas vaginalis</i>, <i>Neisseria gonorrhoeae</i>, herpes simplex virus types 1 and 2 (HSV-1/2), <i>Mycoplasma</i>, <i>Ureaplasma</i>, <i>Candida species</i> and HPV. Overall, 26.8% (95% confidence interval (CI): 23.7-29.9) of women tested positive for BV or one of the following STIs: <i>C. trachomatis</i>, <i>T. vaginalis</i>, <i>N. gonorrhoeae</i>, <i>Mycoplasma genitalium</i>, HSV-1/2 or <i>Ureaplasma urealyticum</i>. Additionally, 22.1% tested positive for at least one high-risk HPV type. <i>Chlamydia trachomatis</i> and HSV-2 were significantly more common among women who were positive for HPV and high-risk HPV. This study reveals a high prevalence of asymptomatic pregnant women who are positive for BV, STIs or HPV, putting them at risk of adverse pregnancy outcomes, secondary infertility or cervical cancer in a country with limited medical coverage. Screening and treating these women could be crucial in reducing morbidity.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1783"},"PeriodicalIF":1.2,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The regional cancer spectrum in Uganda: a population-based cancer survey by sub-regions (2017-2020). 乌干达的区域癌症谱:按次区域进行的基于人口的癌症调查(2017-2020 年)。
IF 1.2
ecancermedicalscience Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1782
Francis Okongo, Catherine Amuge, Alfred Jatho, Nixon Niyonzima, David Martin Ogwang, Jackson Orem
{"title":"The regional cancer spectrum in Uganda: a population-based cancer survey by sub-regions (2017-2020).","authors":"Francis Okongo, Catherine Amuge, Alfred Jatho, Nixon Niyonzima, David Martin Ogwang, Jackson Orem","doi":"10.3332/ecancer.2024.1782","DOIUrl":"10.3332/ecancer.2024.1782","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Accurate estimation of the burden of cancer in developing countries is a major public health concern for cancer prevention and control because of the limited coverage of population-based cancer registries (PBCRs). The cancer registration coverage status of Uganda was 11.90% and was not uniformly distributed in all regions of Uganda. This population-based survey was conducted to assess the burden of cancer in all the sub-regions of Uganda by site, sex and age group to accurately determine the cancer profile of Uganda by sub-region for a tailored intervention to mitigate cancer risk factors and burden.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study used existing administrative units of Uganda from which 55 districts emerged, forming 10 sub-regions as satellite population-based cancer registry study sites. Data on newly diagnosed cancer cases were retrospectively collected for the period 2017-2020 using a cancer notification form, entered into CanReg5 Software, exported to spreadsheets and univariate analysis was performed to determine the cancer spectrum, their proportions and crude rates by site, sex, age group and geographical location.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 25,576 cancer cases were registered, up to 14,322 (56%) were in females and, male cancers were 11,254 (44%). The top five female cancers in all the sub-regions included cervical cancer (43%, &lt;i&gt;n&lt;/i&gt; = 6,190), breast (22%, &lt;i&gt;n&lt;/i&gt; = 3,200), esophagus (5.6%, &lt;i&gt;n&lt;/i&gt; = 800), ovary (5.2%, &lt;i&gt;n&lt;/i&gt; = 746), Kaposi Sarcoma (KS) (4.7%, &lt;i&gt;n&lt;/i&gt; = 666) and other less common cancers (18.5%, &lt;i&gt;n&lt;/i&gt; = 2,720). In males, the top five cancers included prostate cancer 25.1 % (&lt;i&gt;n&lt;/i&gt; = 2,820), esophagus 15.1% (&lt;i&gt;n&lt;/i&gt; = 1,704), KS 12.4% (&lt;i&gt;n&lt;/i&gt; = 1,395), liver 8.8% (&lt;i&gt;n&lt;/i&gt; = 989) and stomach 4.8% (&lt;i&gt;n&lt;/i&gt; = 539), with other less common male cancers accounting for 33.8% (&lt;i&gt;n&lt;/i&gt; = 3,807).In all the sub-regions of Uganda, cancers of the esophagus, liver and KS are common in both males and females, but the number of males with these cancers is twice that of their female counterparts. In Rwenzori, Kigezi and Bugishu sub-Regions, there seems to be an increased risk of developing other skin cancers in females, while stomach cancers have been reported in both males and females. Most of the other sub-regions register emerging cases of only ovarian cancer in females. In children, the top three cancers included lymphoma, 33.9% (&lt;i&gt;n&lt;/i&gt; = 653); soft tissue sarcomas, 20.8% (&lt;i&gt;n&lt;/i&gt; = 400); malignant bone tumors, 15.8% (&lt;i&gt;n&lt;/i&gt; = 305); myeloid-type leukemia, 13.8% (&lt;i&gt;n&lt;/i&gt; = 265); and the other less common childhood cancers combined, 15.7% (&lt;i&gt;n&lt;/i&gt; = 303). The proportion of childhood cancers is higher in the male child compared to the female at a ratio of 1.3:1.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The sub-regional cancer spectrum in Uganda ranges from cervical cancer to breast, esophageal, ovarian and KS in females. Male cancers include prostate, esophage","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1782"},"PeriodicalIF":1.2,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can combined paravertebral and erector spinae block provide perioperative analgesia for mastectomy with LD flap reconstruction surgery? An observational study. 椎旁和竖脊肌联合阻滞能否为乳房切除LD皮瓣重建手术提供围手术期镇痛?一项观察性研究。
IF 1.2
ecancermedicalscience Pub Date : 2024-09-27 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1781
Arunangshu Chakraborty, Sanjit Agrawal, Shiladitya Bose, Rosina Ahmed, Rakhi Khemka
{"title":"Can combined paravertebral and erector spinae block provide perioperative analgesia for mastectomy with LD flap reconstruction surgery? An observational study.","authors":"Arunangshu Chakraborty, Sanjit Agrawal, Shiladitya Bose, Rosina Ahmed, Rakhi Khemka","doi":"10.3332/ecancer.2024.1781","DOIUrl":"10.3332/ecancer.2024.1781","url":null,"abstract":"<p><strong>Background: </strong>Mastectomy and breast reconstruction with latissimus dorsi myocutaneous flap (LDF) is a major surgery that covers eight or more dermatomes causing severe pain in the postoperative period.</p><p><strong>Objectives: </strong>We evaluated the analgesic effect of a hybrid technique of ultrasound-guided combined thoracic paravertebral block (TPVB) and erector spinae plane block (ESPB) in a single needle pass in ten consecutive patients scheduled for mastectomy with LDF reconstruction as a part of a multimodal analgesia regimen.</p><p><strong>Design: </strong>Prospective observational study.</p><p><strong>Setting: </strong>A tertiary-level cancer hospital in Eastern India. The study was conducted between 01/09/2023 and 20/12/2023.</p><p><strong>Patients: </strong>10 consecutive consenting female patients of age between 18 and 75 years suffering from breast cancer, scheduled for a mastectomy with LDF reconstruction were recruited in this study, excluding patients with body mass index more than 40, coagulopathy or thrombocytopenia, skin conditions such as dermatitis, infection and so on, and known allergy to local anaesthetics (LAs).</p><p><strong>Interventions: </strong>The recruited patients received an ultrasound-guided combined thoracic paravertebral and erector spinae (COMPARES) block at the third thoracic (T3) level in a single needle pass, with 10 mL in the TPVB and 30 mL in the ESPB compartment, respectively, in a cephalad to caudad approach before induction of general anaesthesia.</p><p><strong>Main outcome measures: </strong>The primary endpoint was pain score at 9:00 am on postoperative day one. Other outcome measures were pain scores at postoperative hours 0 (immediately after awakening from general anaesthesia), 4, 8 and 12, postoperative nausea vomiting, requirement of rescue analgesics and pain score on shoulder movements on postoperative day one.</p><p><strong>Results: </strong>Median (range) resting pain scores at 0, 4, 8 and 24 hours were 1.5 (0-5), 2.5 (0-4), 2.5 (2-5) and 3 (2-4), and dynamic pain score on shoulder mobilization on postoperative day one morning was 3 (2-6). Only one patient required rescue analgesia.</p><p><strong>Conclusions: </strong>We found the technique inexpensive and potentially useful, but difficult in obese and short-statured patients due to increased depth and narrowing of the intertransverse space. This technique should be further evaluated in a randomised controlled trial.</p><p><strong>Trial registration: </strong>This trial was registered with the Clinical Trials Registry of India with the registration number CTRI/2023/08/057119.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1781"},"PeriodicalIF":1.2,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinicopathological features associated with CD44 and CD63 expression in breast cancer. 与乳腺癌中 CD44 和 CD63 表达相关的临床病理特征
IF 1.2
ecancermedicalscience Pub Date : 2024-09-26 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1779
Carlos A Castaneda, Miluska Castillo, Joselyn Sanchez, Luis Bernabe, Katherin Tello, Nancy Suarez, Raul Alatrista, Ximena Quiroz-Gil, Alexandra Granda-Oblitas, Javier Enciso, Nathaly Enciso, Henry L Gomez
{"title":"Clinicopathological features associated with CD44 and CD63 expression in breast cancer.","authors":"Carlos A Castaneda, Miluska Castillo, Joselyn Sanchez, Luis Bernabe, Katherin Tello, Nancy Suarez, Raul Alatrista, Ximena Quiroz-Gil, Alexandra Granda-Oblitas, Javier Enciso, Nathaly Enciso, Henry L Gomez","doi":"10.3332/ecancer.2024.1779","DOIUrl":"10.3332/ecancer.2024.1779","url":null,"abstract":"<p><strong>Background: </strong>CD44 is a cell-surface transmembrane glycoprotein that participates in the regulation of many cellular processes, including cell division, adhesion, migration and stem-like characteristics. CD63 is involved in the exocytosis process.</p><p><strong>Objective: </strong>To evaluate the relationship between CD44 and CD63 expression and clinicopathological features, including tumor-infiltrating lymphocytes (TILs), phosphoinositide 3-kinase (PIK3CA) mutation and survival.</p><p><strong>Methodology: </strong>CD44 and CD63 were stained in samples from 101 breast cancer cases from Peruvian women.</p><p><strong>Results: </strong>Median age was 52 years, most were most were grade-3 (68%), estrogen receptor (ER)+ (64%) and stage II-III (92%). Median ki67 was 30%, median stromal TIL was 30% and <i>PIK3CA</i> mutation was found in 49%. Longer survival was associated with earlier stages (<i>p</i> = 0.016), lower ki67 (<i>p</i> = 0.023), ER+ (<i>p</i> = 0.034), luminal phenotype (<i>p</i> = 0.029) and recurrence (<i>p</i> < 0.001). CD44 was classified as high cell density staining in 57% and high intensity in 55%. High CD44 density was associated with younger age (<i>p</i> = 0.043), triple-negative phenotype (<i>p</i> = 0.035) and shorter survival (<i>p</i> = 0.005). High CD44 expression was associated with short survival (<i>p</i> = 0.005). High CD63 cell density was found in 56% of cases and was associated with ER-positive (<i>p</i> = 0.045), low TIL levels (<i>p</i> = 0.007), Luminal-A (<i>p</i> = 0.015) and low CD44 intensity (<i>p</i> = 0.032).</p><p><strong>Conclusion: </strong>CD44 expression was associated with aggressive features and low CD63 density staining.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1779"},"PeriodicalIF":1.2,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
African colorectal cancer burden in 2022 and projections to 2050. 2022 年非洲结直肠癌发病率及到 2050 年的预测。
IF 1.2
ecancermedicalscience Pub Date : 2024-09-26 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1780
Mounoume Lobe Irma Louise Virginie, Qiu Zhao, Lan Liu
{"title":"African colorectal cancer burden in 2022 and projections to 2050.","authors":"Mounoume Lobe Irma Louise Virginie, Qiu Zhao, Lan Liu","doi":"10.3332/ecancer.2024.1780","DOIUrl":"10.3332/ecancer.2024.1780","url":null,"abstract":"<p><strong>Introduction: </strong>The burden of colorectal cancer (CRC) is on a rapid increase on the African continent, yet grossly under reported. Herein, we provide and updated estimates of CRC burden (incidence and mortality) across Africa as of 2022, and make crucial predictions to 2050.</p><p><strong>Methods: </strong>We gathered information on CRC incidence and mortality from the GLOBOCAN 2022 database, which covers 185 countries. The age-standardised incidence and mortality rates (ASRs) per 100,000 person-years were determined. Cases and deaths up to 2050 were estimated using 2022 incidence and mortality rates.</p><p><strong>Results: </strong>In 2022, an estimated 70,428 cases and 46,087 mortalities due to CRC were recorded across the African continent. Africa's ASRs for CRC incidence and mortality were 8.2 and 5.6 per 100,000 population, respectively, and were highest in North Africa followed by East Africa. At national levels, CRC ranked in the top four of the most commonly diagnosed cancers in more than half (56%) of African countries. ASRs of both incidence and mortality were higher among males than females. New cases are predicted to increase by 139.7% (from 70,428 in 2022 to 168,683 in 2050) at the current incidence rate. Similarly, mortalities will increase by 155.2% (from 46,061 in 2022 to 117,568 in 2050).</p><p><strong>Conclusion: </strong>CRC remains a major cause of morbidity and mortality in many African countries, and the number of new cases and deaths is predicted to rise significantly by 2050. Efforts to reduce the incidence of preventable CRC cases should be prioritised.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1780"},"PeriodicalIF":1.2,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors influencing tobacco quitting: findings from National Tobacco-Quitline Services, Mumbai, India. 影响戒烟的因素:印度孟买全国戒烟热线服务的调查结果。
IF 1.2
ecancermedicalscience Pub Date : 2024-09-25 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1777
Atul Budukh, Sharyu Mhamane, Sonali Bagal, Priyal Chakravarti, Ganesh Ogale, Radhika Sharma, Manisha Yadav, Sushama Saoba, Suvarna Gore, Pankaj Chaturvedi
{"title":"Factors influencing tobacco quitting: findings from National Tobacco-Quitline Services, Mumbai, India.","authors":"Atul Budukh, Sharyu Mhamane, Sonali Bagal, Priyal Chakravarti, Ganesh Ogale, Radhika Sharma, Manisha Yadav, Sushama Saoba, Suvarna Gore, Pankaj Chaturvedi","doi":"10.3332/ecancer.2024.1777","DOIUrl":"10.3332/ecancer.2024.1777","url":null,"abstract":"<p><p>The Government of India established National Tobacco Quitline Services (NTQLS) to provide free and effective telephonic counselling to help people quit tobacco. The objective of the paper is to present the data of tobacco quitters who quit tobacco through NTQLS, Mumbai, in the years 2021-2022 and the factors that influenced tobacco quitting. This is a prospective study where individuals willing to quit tobacco utilised NTQLS. Effective counselling was provided and was followed up. Multiple logistic regression analysis was conducted. Tobacco quitting is the dependent variable while sociodemographic characteristics, tobacco consumption habits, previous quit attempts, alcohol consumption, other substance use and co-morbidity were independent variables. In the years 2021-2022, a total of 448,893 calls hit the system. Of these, 127,163 (28.3%) calls were attended. Of the attended calls, a quit date was set for 21,504 calls (16.9%); of these, 8,276 (38.5%) callers quit tobacco. Individuals with no previous quit attempts [OR: 1.48, 95% confidence interval (CI): 1.25-1.75], never consumed alcohol (OR: 1.37, 95%CI: 1.2-1.56), consumed tobacco within 6-30 minutes (OR: 1.29, 95% CI: 1.12-1.49) and 30-60 minutes after waking up (OR: 1.26, 95% CI: 1.05-1.51) had higher quitting rates. While, female callers (OR: 0.59, 95% CI: 0.35-0.99), private sector workers (OR: 0.70, 95% CI: 0.61-0.81), individuals consuming more than ten tobacco units/packets (OR: 0.70, 95% CI: 0.61-0.79), tobacco use more than 10 years (OR: 0.85, 95% CI: 0.73-0.97), expenditure of more than 5,000 rupees on tobacco (OR: 0.58, 95% CI: 0.44-0.77) and those with no known co-morbid conditions (OR: 0.8, 95% CI: 0.71-0.91) were less likely to quit tobacco. Reduced tobacco consumption will inadvertently reduce the non-communicable disease (NCD) burden and help in achieving the sustainable development goals related to tobacco control and NCD. Quitline plays an important role in tobacco control.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1777"},"PeriodicalIF":1.2,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incorporating a mobile application to support communication about HPV testing among women and professionals: barriers and facilitators from the perspective of health professionals in a middle- and low-income setting in Argentina. 纳入移动应用程序,支持妇女和专业人员之间就人类乳头瘤病毒检测进行交流:从阿根廷中低收入环境中医疗专业人员的角度看障碍和促进因素。
IF 1.2
ecancermedicalscience Pub Date : 2024-09-25 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1778
Lucila Szwarc, Paula Frejdkes, Victoria Sánchez Antelo, Melisa Paolino, Silvina Arrossi
{"title":"Incorporating a mobile application to support communication about HPV testing among women and professionals: barriers and facilitators from the perspective of health professionals in a middle- and low-income setting in Argentina.","authors":"Lucila Szwarc, Paula Frejdkes, Victoria Sánchez Antelo, Melisa Paolino, Silvina Arrossi","doi":"10.3332/ecancer.2024.1778","DOIUrl":"10.3332/ecancer.2024.1778","url":null,"abstract":"<p><strong>Introduction: </strong>The delivery of positive Human papillomavirus (HPV) test results can have a psychosocial impact and act as a barrier for women to continue the cervical cancer (CC) prevention process. A previous formative research based on a woman's perspective indicated that a mobile app could be an acceptable and appropriate tool to help women obtain information and reduce fears related to a positive result. Based on these findings, we developed an app-based intervention that would function as a support for professionals who offer the HPV test and communicate their results. We report data on the perceptions of healthcare providers regarding the barriers and facilitators to the incorporation, in a low and middle-income context.</p><p><strong>Methods: </strong>Qualitative study based on individual semi-structured interviews with health professionals. All the professionals (<i>n</i> =13) took HPV and Pap test samples and provided information on HPV testing, in the public health system of Ituzaingó, Greater Buenos Aires, Argentina. The themes explored were selected and analysed using domains and constructs of Consolidated Framework for Implementation Research (CFIR).</p><p><strong>Results: </strong>Practitioners had a positive assessment of the intervention through most included constructs: adaptability, compatibility, complexity, relative advantage, belief in the validity and robustness of the intervention, innovation source and knowledge and beliefs about the intervention. However, some potential barriers were also identified including: adaptability, tensions for change, relative priority and leadership engagement. Practitioners conditioned the intervention's success to specific adjustments of the app (weight and interface usability), legitimmated institutions' support, and clear and sustained health authorities' commitment and directions.</p><p><strong>Conclusion: </strong>Health professionals had a positive assessment of implementing an app to support the HPV test communication and information provision process, although they conditioned its effectiveness to specific adjustments. The results allow us to identify and develop recommendations for the app to be implemented effectively and sustained over time. The findings of this study have important implications not only for Argentina, but also for other low and middle-income countries, given that the implementation could be adapted, with the aim of improving communication between patients and health institutions in the CC prevention process.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1778"},"PeriodicalIF":1.2,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pattern of care and treatment outcomes of metastatic non-clear cell kidney cancer: a single centre experience from India. 转移性非透明细胞肾癌的护理模式和治疗效果:印度单一中心的经验。
IF 1.2
ecancermedicalscience Pub Date : 2024-09-23 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1775
Somnath Roy, Sreejata Raychaudhuri, Bivas Biswas, Deepak Dabkara, Arnab Bhattacherjee, Sandip Ganguly, Joydeep Ghosh, Yesha Sandipbhai Patel, Souhita Pal, Jagriti Karmakar, Anindita Mitra, Sujoy Gupta
{"title":"Pattern of care and treatment outcomes of metastatic non-clear cell kidney cancer: a single centre experience from India.","authors":"Somnath Roy, Sreejata Raychaudhuri, Bivas Biswas, Deepak Dabkara, Arnab Bhattacherjee, Sandip Ganguly, Joydeep Ghosh, Yesha Sandipbhai Patel, Souhita Pal, Jagriti Karmakar, Anindita Mitra, Sujoy Gupta","doi":"10.3332/ecancer.2024.1775","DOIUrl":"10.3332/ecancer.2024.1775","url":null,"abstract":"<p><strong>Background: </strong>Non-clear-cell renal cell carcinoma (nccRCC) refers to a rare diverse heterogeneous group of tumours; usually treated with immune check point inhibitors and or tyrosine kinase inhibitors (TKIs). Prospective large-scale data from Asian countries is limited.</p><p><strong>Methods: </strong>This is a retrospective study of patients with metastatic nccRCC treated at Tata Medical Centre, Kolkata, India, from 2012 to 2022. Demographic profiles, histologic subtypes, treatment details, response to therapy (by response evaluation criteria in solid tumours (RECIST v1.1)) and survival status were captured from electronic medical records (EMRs) of hospitals up till May 2023. Kaplan Meier methods were estimated to assess progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>A total of 89 consecutive patients were screened for this study, 24 were excluded due to inadequate data in EMR. 65 patients were included in the final analysis, with a median age at diagnosis of 59 years (range 20-84) of which 81% were male. Histologic subtypes comprised of 43% papillary, 31% clear cell with mixed histology, 3% sarcomatoid and 23% others including chromophobe, mucinous-tubular, spindle cell, oncocytic, medullary, poorly differentiated and rhabdoid). The most common site of metastasis was the lung 62% (<i>n</i> = 40) followed by non-regional nodes 32%, bone 26% and liver 14%. 15% patients presented with haematuria and 62% underwent nephrectomy prior to systemic therapy. The majority received pazopanib 46% (<i>n</i> = 30), chemotherapy 20% (<i>n</i> = 13) including bevacizumab plus erlotinib, sunitinib 15% (<i>n</i> = 10) or cabozantinib 14% (<i>n</i> = 9). Only 3(5%) patients received nivolumab plus cabozantinib combination. Response to treatment showed complete response in 1.5%, partial response in 20%, stable disease in 51% and progressive disease in 23% as per RECIST v1.1. 17 patients required dose reduction and interruption due to adverse effects and 33% (<i>n</i> = 22) received second-line therapy with nivolumab 18% (<i>n</i> = 4), axitinib and everolimus among others. After a median follow up of 44 months, the median PFS was 13 months (95%CI 7.2-18.9) and the median OS was 17 months (95%CI 12.1-22.1) for the entire cohort.</p><p><strong>Conclusion: </strong>The overall response and survival for metastatic nccRCC was relatively better in comparison with published data, despite the limited number of patients treated with ICIs due to cost and access barriers.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1775"},"PeriodicalIF":1.2,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信